drugset / Trial / NCT02356224
The PK/PD Study of Single Dose of SHR3824 in Healthy Volunteers
RandomizedParallel-groupQuadruple-blindTreatment
Summary
SHR3824 is a novel inhibitor of renal sodium-glucose cotransporter 2, allows an insulin-independent approach to improve type 2 diabetes hyperglycemia. In this single-dose study the investigators evaluated the safety, tolerablity and PK/PD profiles of SHR3824 in healthy subjects.
Timeline
- Start
- 2013-06
- Primary completion
- 2013-12
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Henagliflozin | Small molecule | 2.5 mg | — |
| Subject | Henagliflozin | Small molecule | 5 mg | — |
| Subject | Henagliflozin | Small molecule | 10 mg | — |
| Subject | Henagliflozin | Small molecule | 25 mg | — |
| Subject | Henagliflozin | Small molecule | 50 mg | — |
| Subject | Henagliflozin | Small molecule | 100 mg | — |
| Subject | Henagliflozin | Small molecule | 200 mg | — |